Bristol Myers, J&J’s new blood thinner fails first big test
Milvexian’s failure in acute coronary syndrome trials has raised significant concerns regarding the future of…
Newswire
Advocates decry intersex exceptions in trans health bans
Recent legislative measures aimed at restricting transgender healthcare have sparked significant backlash, particularly concerning the…
Bristol Myers, J&J’s Next-Gen Blood Thinner Fails Key Trial in Another Setback for Factor XI
In a significant blow to the pharmaceutical industry’s efforts to develop safer anticoagulants, Bristol Myers…
Pfizer Reduces Stake in BioNTech; Candel Pauses Pancreatic Cancer Program
Pfizer has reduced its stake in BioNTech, now holding approximately $163.5 million in shares following…
Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal
Pfizer has finalized a $10 billion acquisition of Metsera, decisively outbidding Novo Nordisk in a…
MSD bets big on flu antivirals with $9.2bn buyout of Cidara
MSD has announced a significant $9.2 billion acquisition of Cidara Therapeutics, marking its second major…
FDA restricts Sarepta’s gene therapy Elevidys after Duchenne patient deaths
The FDA has imposed new restrictions on Sarepta Therapeutics’ gene therapy, Elevidys, following reports of…
NIH Places Outspoken Critic of Trump Administration on Leave
A vocal critic of the Trump administration’s policies at the National Institutes of Health (NIH)…
More Americans Use Weight Loss Drugs Like Ozempic Than Live in Texas
Recent data reveals that the number of Americans utilizing weight loss medications, particularly GLP-1 receptor…
Merck Acquires Cidara Therapeutics for $9.2 Billion Amid Patent Concerns
Merck has agreed to acquire Cidara Therapeutics, the developer of an experimental flu therapy, in…